

# Product News

## **MeVis Medical Solutions AG releases Veolity 1.1**

### Veolity 1.1 supports ACR Lung-RADS and segmentation of part-solid lung nodules

**Bremen/Germany, May 13, 2015** – Early detection of lung cancer helps save lives. In the U.S., leading market of medical technology, CT lung cancer screening was approved by the U.S. Centers for Medicare & Medicaid Services (CMS) in the fourth quarter of 2015. Screening programs have already been started. European countries are expected to follow.

With the newly released Veolity version 1.1, [MeVis Medical Solutions AG](#) continues to support imaging centers to handle the vast number of clients, and to implement lung cancer screening guidelines and quality requirements.

Veolity is a vendor-neutral CT image analysis software application, designed for efficient reading and reporting workflow in a high throughput environment like CT lung cancer screening. It brings together lung CAD (computer-aided detection) of solid pulmonary nodules, integration and automatic registration of prior studies, and semi-automatic nodule segmentation.

The new release Veolity 1.1 provides these major features:

- Full support for the ACR (American College of Radiology) Lung-RADS 1.0 reporting standard
- Semi-automatic nodule segmentation for part-solid findings
- Solid and non-solid nodule segmentation including automated measurements of volumes and diameters
- Automated propagation of prior findings
- Integration of incidental findings
- Seamless interfacing with clinical infrastructure like PACS and patient management systems

The automatically generated reports now follow the current ACR Lung-RADS standard, provide nodule malignancy prediction, and give guidance on determining patient follow-up.

"We are confident that the inclusion of the ACR Lung-RADS standard into Veolity will be of tremendous help for lung cancer screening programs. Veolity finally provides all tools and information required to properly manage the follow-up of the screening participants," says Bernd Kuemmerlen, product manager, MeVis Medical Solutions AG.

For more information about Veolity, and to arrange a demonstration or a trial installation, please visit <http://www.veolity.com/contact/>.

**About Veolity**

[www.veolity.com](http://www.veolity.com)

**About MeVis Medical Solutions AG**

[www.mevis.de](http://www.mevis.de)

**Contact:**

MeVis Medical Solutions AG

Martina Hallmann

Public Relations

Caroline-Herschel-Str. 1

28359 Bremen, Germany

Phone: +49 421 22495-301

E-mail: [martina.hallmann@mevis.de](mailto:martina.hallmann@mevis.de)

\*\*\*\*\*

*MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.*

*Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.*